Related Experiment Video
Updated: Jun 22, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders
Dawn Eggert1, Prasanta K Dash, Nawal Serradji
1Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5880, USA.
Abstract:
The neuroregulatory activities of PMS-601, a platelet activating factor antagonist, were investigated in laboratory and animal models of HIV-1 encephalitis (HIVE). For the former, PMS-601 reduced monocyte-derived macrophage pro-inflammatory secretions, multinucleated giant cell (MGC) formation, and neuronal loss independent of antiretroviral responses. PMS-601 treatment of HIVE severe combined immunodeficient mice showed reduced microgliosis, MGCs and neurodegeneration. These observations support the further development of PMS-601 as an adjunctive therapy for HIV-1 associated neurocognitive disorders.
Related Concept Videos
Alzheimer's Disease: Treatment
Cryptococcal Meningitis
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

